DuPont recently announced it has completed the previously announced divestiture of its Aramids business (Kevlar^® and Nomex^®) to Arclin, a portfolio company of an affiliate of TJC, L.P. (TJC). The transaction valued the business at approximately $1.8 billion.

With the close of the transaction, DuPont receives pretax cash proceeds of approximately $1.2 billion, subject to customary transaction adjustments, a note receivable of $300 million, and a non-controlling common equity interest in Arclin currently valued at $325 million, which is expected to represent an approximate 16% stake.

The results of the Aramids business were reclassified and reported as discontinued operations beginning in third quarter 2025 for current and historical periods.

Learn more about Arclin at www.arclin.com. For additional information about TJC, visit www.tjclp.com. Learn about DuPont at www.dupont.com